Light-Activated drug tested in battle against rare cancer
NCT ID NCT02153229
Summary
This study is testing whether adding a special light-activated drug treatment during surgery helps people with a specific type of lung cancer (epithelioid malignant pleural mesothelioma) live longer. All participants have surgery to remove as much cancer as possible, followed by chemotherapy. Half also receive the light therapy during their operation. The main goal is to see if the light therapy improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOD MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.